Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.8% year on year to $194.3 million. On the ...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
StockStory.org on MSN
Why Repligen (RGEN) stock is trading up today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 2.9% in the afternoon ...
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do ...
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the ...
The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results